This is capitulation ! BUY now It is quite apparent that PFE and the vaccine space as a whole is witnessing capitulation. Details are explained in the video as to why a major bottom is forming.
Pfizerlong
$PFE | Allocation/Buy Trade | Market Exec |Technical Confluences:
- Price is in Oversold Conditions in D1 timeframe
- Price action bouncing off 150% Fibo Extension
- Price is trying to go back above the Interest Zone to give some bullish momentum to the stock
Fundamental Confluences:
-Regardless how bad the negative rumours are ongoing about the side-effects from Pfizer; they are still considered a strong market leader in the Pharma industry
- They had a good response on a testing of their recent respiratory drug
- Value?
----
Health sector in your Portfolio will never be wrong with the global aging population.
I am putting this trade on as either into my Long-Term Portfolio or Swing trade for $PFE.
Depending on how market develops, I may decide to hold this bag and allocate more into it at the 178% Fibo Extension levels or cut my Buy position as shown.
-----
$PFE (Pfizer Inc) - Double Bottom and Missing RetestIt seems like the price may have hit its bottom, as we're seeing two Key Reversals on the Monthly timeframe.
This scenario could signal a Double Bottom, setting the stage for a high-probability trade setup with waiting for the price to break through the recent Lower High (LH) to confirm a change in trend.
Shifting our focus to the Daily timeframe, there are few potential Sniper Entries opportunities offering the promise of substantial rewards 💸
Pfizer - Watch The SupportHello Traders, welcome to today's analysis of Pfizer.
--------
Explanation of my video analysis:
All the way back in 2012 Pfizer created a massively bullish triangle reversal pattern at the $17.00 level. This was followed by a +200% rally. Since 2022 Pfizer has been dropping significantly and is now retesting the support level which I mentioned in the analysis. If we see bullish conformation on the smaller timeframes, this might be an interesting long trading setup.
--------
I will only take a trade if all the rules of my strategy are satisfied.
Let me know in the comment section below if you have any questions.
Keep your long term vision.
PFIZER - Weekly - TIME TO BUY?PFIZER - Weekly - TIME TO BUY?
These are my keylevels on weekly time frame , the price its almost on monthly support where i will add some aditional shares on my portfolio
Pfizer (PFE) -> It Is Now Or NeverMy name is Philip, I am a German swing-trader with 4+ years of trading experience and I only trade stocks , crypto , options and indices 🖥️
I only focus on the higher timeframes because this allows me to massively capitalize on the major market swings and cycles without getting caught up in the short term noise.
This is how you build real long term wealth!
In today's anaylsis I want to take a look at the bigger picture on Pfizer.
At the moment Pfizer stock is once again retesting major sructure at the psychological $33 level which already acted as pretty strong support in the past.
Considering that the next support level below current price is at $27, Pfizer is now trading at a pretty decisive potential turning point and has not yet broken structure towards the downside.
- - - - - - - - - - - - - - - - - - - -
I know that this is a quite simple trading approach but over the past 4 years I've realized that simplicity and consistency are much more important than any trading strategy.
Keep the long term vision🫡
Unveiling the Potential of Pfizer Pharmaceutical Stock in 2023Are you searching for a lucrative investment opportunity that promises great returns in 2023? Look no further as we unveil the hidden potential of Pfizer Pharmaceutical stock. In this blog post, we will delve into the compelling reasons why investing in Pfizer is not only a smart move but also an incredibly exciting. From groundbreaking innovations to robust financial performance, join us as we explore why Pfizer is poised to be a game-changer in the pharmaceutical industry and how you can reap substantial rewards by including it in your investment portfolio. Don’t miss out on this exclusive insight into what could be your most profitable venture yet!
Monthly price action is supporting a strong bullish correction in the following months. Pfizer is one of the world’s leading pharmaceutical companies and was at the forefront of developing a vaccine for Covid-19 in 2020. The stock price reflected the impact of the vaccine until December 2021, when the stock plunged, losing almost 50% of its value. It’s then when a longer-term demand imbalance takes control and helps us make a high-probability decision to buy and hold shares of Pfizer PFE stock.
Pfizer getting ready to make rapid movesPfizer is one of the world’s leading pharmaceutical company specializes in vaccines, hospitals, internal medicines and inflammation and immunology. Their manufacturing capacity is 4 billion tablets annually and supplied in neighboring countries of India.
Pfizer CMP is 3866. Negative aspects of the company are high valuation (P.E. = 28.3), MFs are decreasing stake. Positive aspects of the company are increasing annual net profits, improving cash from operations annual, no debt, FIIs are increasing stake and zero promoter pledge.
Entry can be taken after closing above 3901. Targets in the stock will be 3975 and 4006. Long term target in the stock will be 4069 and 4129. Stop loss in the stock should be maintained at closing below 3696.
PFE long positionThe price has been traded in a downnsloping channel .
We expect the bounce from the donwsloping support.
Spelucative long position:
entry: 38,43
target: 47,82
stop loss: 37,49
Pfizer BullishThe Chart currently shows Bullish signal as per these indicators:
1. Bullish Falling Wedge Chart Pattern
2. Bullish Divergence ( RSI )
If the upper trendline is broken can expect further upside potential.
Pfizer in a bull flag.Pfizer - 30d expiry - We look to Buy a break of 48.31 (stop at 46.56)
Short term bias has turned positive.
Posted a bullish Flag formation.
A break of 48.26 is needed to confirm the outlook.
A break of the recent high at 48.26 should result in a further move higher.
Short term momentum is bullish.
This stock has seen good sales growth.
The bias is to break to the upside.
Our profit targets will be 52.69 and 53.69
Resistance: 48.00 / 49.70 / 52.00
Support: 46.70 / 46.00 / 44.70
Disclaimer – Saxo Bank Group.
Please be reminded – you alone are responsible for your trading – both gains and losses. There is a very high degree of risk involved in trading. The technical analysis , like any and all indicators, strategies, columns, articles and other features accessible on/though this site (including those from Signal Centre) are for informational purposes only and should not be construed as investment advice by you. Such technical analysis are believed to be obtained from sources believed to be reliable, but not warrant their respective completeness or accuracy, or warrant any results from the use of the information. Your use of the technical analysis , as would also your use of any and all mentioned indicators, strategies, columns, articles and all other features, is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness (including suitability) of the information. You should assess the risk of any trade with your financial adviser and make your own independent decision(s) regarding any tradable products which may be the subject matter of the technical analysis or any of the said indicators, strategies, columns, articles and all other features.
Please also be reminded that if despite the above, any of the said technical analysis (or any of the said indicators, strategies, columns, articles and other features accessible on/through this site) is found to be advisory or a recommendation; and not merely informational in nature, the same is in any event provided with the intention of being for general circulation and availability only. As such it is not intended to and does not form part of any offer or recommendation directed at you specifically, or have any regard to the investment objectives, financial situation or needs of yourself or any other specific person. Before committing to a trade or investment therefore, please seek advice from a financial or other professional adviser regarding the suitability of the product for you and (where available) read the relevant product offer/description documents, including the risk disclosures. If you do not wish to seek such financial advice, please still exercise your mind and consider carefully whether the product is suitable for you because you alone remain responsible for your trading – both gains and losses.
Accumulating PFE from $46.00 - $47.50 This is one of the stocks I hold indefinitely for dividends.
we're at the bottom of our current channel and a double bottom is forming in a major area of support.
In my previous post I stated my accumulation sections are in the lower end of the channel, so this is prime real estate to enter.
Momentum downwards has come to a halt and I believe we will retest the center channel line from this point.
I am diversifying a portion of profits I made from the last 2 trade set ups I've posted into PFE. A fundamentally sound entity in our current market economy.
I'm sure you could assume why.
pfizer is ready to see $53 pfizer is ready to see $53 , it's in G diametric pattern and it's ready to compete it to make b of flat
Pfizer | Fundamental Analysis | Must ReadSo far this year has not been kind to stock markets. And while many drug makers have avoided a selloff, Pfizer is not one of them. The pharmaceutical giant has performed more or less on par with the broader market to date. Fortunately, Pfizer's latest quarterly report showed some very encouraging signs.
However, there are also reasons to be concerned about the future of this medical company. Let's look at one earnings-related reason why Pfizer might be a buy and one reason why it might not be.
Pfizer has made a fortune over the past couple of years through its work on coronaviruses. The company continues to benefit greatly from these efforts. In Q2, the company's revenues rose 53% year over year to $27.7 billion. According to company executives, Pfizer recorded the largest quarterly sales in its history during the period, and that was primarily due to its COVID-19 product line.
Sales of the coronavirus vaccine totaled $8.8 billion, up 20% from last year. Sales of the coronavirus drug Paxlovid were $8.1 billion (no year-over-year comparison here, since the drug received approval in December). These two drugs alone accounted for more than half of Pfizer's total revenue.
While Pfizer's line of drugs against coronaviruses is currently unparalleled, the rest of the company's portfolio is not as impressive. The non-coronavirus drug maker's revenues grew a paltry 1% year-over-year in Q2. Pfizer's line of drugs faces a number of challenges, including adverse events related to its immunologic drug Xeljanz. Xeljanz belongs to a class of drugs known as JAK inhibitors.
Last year, Pfizer published data from a post-marketing study that showed Xeljanz was associated with higher rates of cardiovascular events and cancer than TNF inhibitors, a drug category that includes AbbVie's Humira.
The results of this study, combined with a regulatory decision to add a warning about these risks to the label of Xeljanz (and other JAK inhibitors), are holding back sales of the drug. In Q2, sales of Xeljanz declined 24% year over year to $430 million. Revenues for the immunosuppressant Enbrel also fell 10% year over year to $257 million, probably because of tougher competition, which also affected its sales in Q1.
Pfizer has some good non-coronavirus numbers, including its drug Eliquis. In Q2, sales of that anticoagulant rose 23% year over year to $1.7 billion. But overall, the company has barely been able to increase sales outside of its line of coronavirus drugs. This could be a problem if sales of COVID-19 products fall sharply after this year.
In my opinion, the market is still underestimating Pfizer. First, the company will continue to make profits from Paclovid and Comirnati. COVID-19 will not (unfortunately) suddenly disappear out of thin air after this year. Even if the demand for drugs to prevent or treat the disease declines, Paxlovid and Komirnati can continue to make significant contributions to Pfizer's top-line revenue for a long time to come.
Second, while the rest of the drug line is unimpressive, pharmaceutical companies sometimes face this problem because of growing competition, patent breaks, or other factors. But drug makers generally don't have the advantage of growing sales at the rate that Pfizer does when they face such obstacles.
What matters is whether the company in question can meet these challenges. Having a solid portfolio and plenty of money to devote to research and development helps - and Pfizer has both. Thanks to the company's success in the coronavirus market, its cash balance has skyrocketed.
Pfizer has been active in acquisitions and plans to continue on that path. This should help bolster its already solid line of drugs, which has more than 90 clinical trials. Pfizer expects up to 15 new approvals over the next 18 months. Some of the current programs could go wrong. But the company has all the tools it needs to launch several new potential blockbuster drugs in the next five years. That's why investors should siphon off the company's stock before it rises in price.
PFE, KO - Very Strong Monthly ChoicesFor anyone looking for a long position in their portfolio (Monthly) Pfizer and Coca-Cola Hodl great potential in their current state
Pfizer has formed a bullflag above the Gaussian Channel
Coca-Cola is very similar above the Channel, however lacking the bullflag
For Coca-Cola check out my previous post below
Pfizer - Bump and RunA larger diversion from the strong trend line occurred in 1994
No further diversions like this have been seen since
This is called a bump and run in a case like this 'Bumping' above the average, and then "running" back to the average
PFE / USD 1D Pfizer - Flying the Bull Flag?Bull flag in the trading sense of the word... I could see a retest of the ATH...Pretty sure the shareholders can too. Bull flag within the ascending broadening wedge pattern may visit around the $55.00 region first. Look at how fast this ones moved though. No surprises eh. Personally not trading this instrument.
PFE Pfizer to All Time HighIf you haven`t bought at my first call, when PFE was $40:
Than you should know that Pfizer’s vaccine with BioNTech SE is on track to be the best-selling drug product on a yearly basis and received backing from a European regulatory panel on Thursday to expand its use into children as young as five.
Still low PE Ratio (TTM) 15.42
Decent Forward Dividend & Yield 1.56 (2.89%)
The stock jumped also on the promise of its antiviral pill!
For me is a Buy even at this level!
PFE potential Monthly Cup and Handle breakout forming.I see potential bigger Cup and Handle forming on PFE . If it does happen , this is going to the moon.
Road to $7.000 in the last Elliot Wave .By the fibonacci retracement we can see how the 0.382 zone made as support, I expect a last impulse in to $7.000
MRNA Moderna vs PFE Pfizer | Head and Shoulders patternIf you haven`t longed Moderna with me from here:
Then you should realize that the head an shoulders pattern on descending volume of a company that worth 53.402B, but has 747Mil negative earnings for 2020, may lead to $100 per share.
On the other hand, undervalued, it`s Pfizer , which has the same amazing results with the vaccine, lots of medicine in the portfolio, a market cap almost 4 times higher, 198.973B and positive earnings of 9.62Bil. The pay also great dividends, btw, 4.38% DIV YIELD on a decent 20.82 P/E ratio .
If you are interested to test some amazing BUY and SELL INDICATORS which give the signal at the beginning of the candle, not at the end of it, just leave me a message.
